Clinical Trial

PSMA-PET Guided Radiotherapy

Study acronym: PSMA-PETgRT
Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated March 13, 2025 (before its estimated May 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
PSMA PET/CT has demonstrated higher sensitivity in detecting metastases than current imaging standard of care (CT and bone scan). \[18F\]DCFPyL is a promising high-sensitivity second generation PSMA-targeted urea-based PET probe. The hypothesis is that definitive radiotherapy (RT) informed by PSMA-PET findings will lead to improved cancer control outcomes compared to RT guided by conventional staging only. This study utilizes cmRCT design in companion to PERA (Partnership initiative for the Evaluation of technological innovation in Radiotherapy).
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2018-05-14; most recent amendment 2025-03-12.
Status change: Recruiting → Active, Not Recruiting 2021-06-07
Status change: Not Yet Recruiting → Recruiting 2018-05-29
Trial Details
NCT Number NCT03525288
Lead Sponsor Centre hospitalier de l'Université de Montréal (CHUM)
Collaborators: Progenics Pharmaceuticals, Inc.
Conditions Prostate Cancer
Enrollment 130 participants
Start Date 2018-05-15
Primary Completion 2026-05-30 (estimated)
Study Completion 2027-05-30 (estimated)
Updated on ClinicalTrials.gov 2025-03-13